Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have been suggested as the potential new class of preventive or therapeutic antitumor agents. The aim of the present study was to evaluate the antitumor activity of the novel NSAID, CG100649. CG100649 is a novel NSAID dual inhibitor for COX-2 and carbonic anhydrase (CA)-I/-II. In the present study, we investigated the alternative mechanism by which CG100649 mediated suppression of the colon cancer growth and development. The anchorage‑dependent and -independent clonogenic assay showed that CG100649 inhibited the clonogenicity of human colon cancer cells. The flow cytometric analysis showed that CG100649 induced the G2/M cell cycle arrest in colon cancer cells. Animal studies showed that CG100649 inhibited the tumor growth in colon cancer xenograft in nude mice. Furthermore, quantitative PCR and FACS analysis demonstrated that CG100649 upregulated the expression of TNF-related apoptosis-inducing ligand (TRAIL) receptors (DR4 and DR5) but decreased the expression of decoy receptors (DcR1 and DcR2) in colon cancer cells. The results showed that CG100649 treatment sensitized TRAIL‑mediated growth suppression and apoptotic cell death. The combination treatment resulted in significant repression of the intestinal polyp formation in APCmin/+ mice. Our data clearly demonstrated that CG100649 contains preventive and therapeutic activity for colon cancer. The present study may be useful for identification of the potential benefit of the NSAID CG100649, for the achievement of a better treatment response in colon cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Anticarcinogenic Agents / pharmacology
-
Anticarcinogenic Agents / therapeutic use*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis / drug effects
-
Cell Line, Tumor
-
Colonic Neoplasms / drug therapy*
-
Colonic Neoplasms / pathology
-
Drug Synergism
-
Female
-
Furans / administration & dosage
-
Furans / pharmacology
-
Furans / therapeutic use*
-
G2 Phase Cell Cycle Checkpoints / drug effects
-
GPI-Linked Proteins / biosynthesis
-
GPI-Linked Proteins / genetics
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Intestinal Polyps / prevention & control
-
Intestine, Small / pathology
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Mice, Inbred C57BL
-
Mice, Nude
-
Neoplasm Proteins / biosynthesis
-
Neoplasm Proteins / genetics
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / biosynthesis
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics
-
Receptors, Tumor Necrosis Factor, Member 10c / biosynthesis
-
Receptors, Tumor Necrosis Factor, Member 10c / genetics
-
Specific Pathogen-Free Organisms
-
Sulfonamides / administration & dosage
-
Sulfonamides / pharmacology
-
Sulfonamides / therapeutic use*
-
TNF-Related Apoptosis-Inducing Ligand / administration & dosage
-
TNF-Related Apoptosis-Inducing Ligand / pharmacology
-
TNF-Related Apoptosis-Inducing Ligand / therapeutic use*
-
Tumor Necrosis Factor Decoy Receptors / biosynthesis
-
Tumor Necrosis Factor Decoy Receptors / genetics
-
Tumor Stem Cell Assay
-
Xenograft Model Antitumor Assays
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Anticarcinogenic Agents
-
Antineoplastic Agents
-
CG100649
-
Furans
-
GPI-Linked Proteins
-
Neoplasm Proteins
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
Receptors, Tumor Necrosis Factor, Member 10c
-
Sulfonamides
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFRSF10A protein, human
-
TNFRSF10C protein, human
-
TNFRSF10D protein, human
-
Tumor Necrosis Factor Decoy Receptors